Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Dr. Martin H. Huber M.D.
Çalışanlar
102
Ülke
Amerika Birleşik Devletleri
ISIN
US59045L1061
Kotasyonlar
0 Comments
Düşüncelerini paylaş
FAQ
Mersana Therapeutics hissesinin bugünkü fiyatı nedir?▼
MRSN’un güncel fiyatı $29.08 USD — son 24 saatte %+0.14% arttı. Mersana Therapeutics hissesinin fiyat performansını grafikte daha yakından izle.
Mersana Therapeutics hissesinin sembolü nedir?▼
Borsaya bağlı olarak hisse sembolü değişebilir. Örneğin, borsasında Mersana Therapeutics hisseleri MRSN sembolüyle işlem görür.